Copyright Reports & Markets. All rights reserved.

Global Flumatinib Mesylate Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Flumatinib Mesylate Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 200 mg/Tablet
    • 1.3.3 400 mg/Tablet
  • 1.4 Market Analysis by Sales Channels
    • 1.4.1 Overview: Global Flumatinib Mesylate Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.4.2 Hospital
    • 1.4.3 Retail pharmacy
    • 1.4.4 Online
  • 1.5 Market Analysis by Pharmaceutical Technology
    • 1.5.1 Overview: Global Flumatinib Mesylate Consumption Value by Pharmaceutical Technology: 2021 Versus 2025 Versus 2032
    • 1.5.2 Innovative drug
    • 1.5.3 Generic drug
  • 1.6 Market Analysis by Application
    • 1.6.1 Overview: Global Flumatinib Mesylate Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Chronic Myeloid Leukemia (CML)
    • 1.6.3 Tyrosine Kinase Inhibitor (TKI)
    • 1.6.4 Others
  • 1.7 Global Flumatinib Mesylate Market Size & Forecast
    • 1.7.1 Global Flumatinib Mesylate Consumption Value (2021 & 2025 & 2032)
    • 1.7.2 Global Flumatinib Mesylate Sales Quantity (2021-2032)
    • 1.7.3 Global Flumatinib Mesylate Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Jiangsu Hansoh Pharmaceutical Group
    • 2.1.1 Jiangsu Hansoh Pharmaceutical Group Details
    • 2.1.2 Jiangsu Hansoh Pharmaceutical Group Major Business
    • 2.1.3 Jiangsu Hansoh Pharmaceutical Group Flumatinib Mesylate Product and Services
    • 2.1.4 Jiangsu Hansoh Pharmaceutical Group Flumatinib Mesylate Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Jiangsu Hansoh Pharmaceutical Group Recent Developments/Updates

3 Competitive Environment: Flumatinib Mesylate by Manufacturer

  • 3.1 Global Flumatinib Mesylate Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Flumatinib Mesylate Revenue by Manufacturer (2021-2026)
  • 3.3 Global Flumatinib Mesylate Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Flumatinib Mesylate by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Flumatinib Mesylate Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Flumatinib Mesylate Manufacturer Market Share in 2025
  • 3.5 Flumatinib Mesylate Market: Overall Company Footprint Analysis
    • 3.5.1 Flumatinib Mesylate Market: Region Footprint
    • 3.5.2 Flumatinib Mesylate Market: Company Product Type Footprint
    • 3.5.3 Flumatinib Mesylate Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Flumatinib Mesylate Market Size by Region
    • 4.1.1 Global Flumatinib Mesylate Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Flumatinib Mesylate Consumption Value by Region (2021-2032)
    • 4.1.3 Global Flumatinib Mesylate Average Price by Region (2021-2032)
  • 4.2 North America Flumatinib Mesylate Consumption Value (2021-2032)
  • 4.3 Europe Flumatinib Mesylate Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Flumatinib Mesylate Consumption Value (2021-2032)
  • 4.5 South America Flumatinib Mesylate Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Flumatinib Mesylate Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Flumatinib Mesylate Sales Quantity by Type (2021-2032)
  • 5.2 Global Flumatinib Mesylate Consumption Value by Type (2021-2032)
  • 5.3 Global Flumatinib Mesylate Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Flumatinib Mesylate Sales Quantity by Application (2021-2032)
  • 6.2 Global Flumatinib Mesylate Consumption Value by Application (2021-2032)
  • 6.3 Global Flumatinib Mesylate Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Flumatinib Mesylate Sales Quantity by Type (2021-2032)
  • 7.2 North America Flumatinib Mesylate Sales Quantity by Application (2021-2032)
  • 7.3 North America Flumatinib Mesylate Market Size by Country
    • 7.3.1 North America Flumatinib Mesylate Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Flumatinib Mesylate Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Flumatinib Mesylate Sales Quantity by Type (2021-2032)
  • 8.2 Europe Flumatinib Mesylate Sales Quantity by Application (2021-2032)
  • 8.3 Europe Flumatinib Mesylate Market Size by Country
    • 8.3.1 Europe Flumatinib Mesylate Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Flumatinib Mesylate Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Flumatinib Mesylate Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Flumatinib Mesylate Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Flumatinib Mesylate Market Size by Region
    • 9.3.1 Asia-Pacific Flumatinib Mesylate Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Flumatinib Mesylate Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Flumatinib Mesylate Sales Quantity by Type (2021-2032)
  • 10.2 South America Flumatinib Mesylate Sales Quantity by Application (2021-2032)
  • 10.3 South America Flumatinib Mesylate Market Size by Country
    • 10.3.1 South America Flumatinib Mesylate Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Flumatinib Mesylate Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Flumatinib Mesylate Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Flumatinib Mesylate Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Flumatinib Mesylate Market Size by Country
    • 11.3.1 Middle East & Africa Flumatinib Mesylate Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Flumatinib Mesylate Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Flumatinib Mesylate Market Drivers
  • 12.2 Flumatinib Mesylate Market Restraints
  • 12.3 Flumatinib Mesylate Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Flumatinib Mesylate and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Flumatinib Mesylate
  • 13.3 Flumatinib Mesylate Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Flumatinib Mesylate Typical Distributors
  • 14.3 Flumatinib Mesylate Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Flumatinib Mesylate market size was valued at US$ 74.08 million in 2025 and is forecast to a readjusted size of US$ 547 million by 2032 with a CAGR of 33.5% during review period.
    In 2025, global production of flumatinib mesylate reached approximately 840,000 units.Flumatinib Mesylate is an oral small-molecule BCR-ABL tyrosine kinase inhibitor (TKI), primarily used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It works by selectively inhibiting the kinase activity of the BCR-ABL fusion protein, thereby blocking tumor cell proliferation signaling pathways and suppressing the growth and spread of leukemic cells.
    Flumatinib mesylate is characterized by strong target specificity and favorable oral bioavailability, and has certain clinical value in both first-line and second-line treatment of chronic myeloid leukemia.
    Flumatinib Mesylate, as a BCR-ABL tyrosine kinase inhibitor (TKI), operates within a mature yet highly competitive segment of the chronic myeloid leukemia (CML) treatment market. With improvements in CML diagnosis and treatment as well as increasing long-term survival rates, the demand for standardized, long-term medication remains strong, providing a stable market foundation for this drug. From a competitive landscape perspective, first- and second-generation TKIs represented by Imatinib, Dasatinib, and Nilotinib have already captured the majority of the market and established a well-developed treatment paradigm. In this context, as a late-entering domestic TKI, flumatinib mesylate needs to gain market share through differentiated advantages in efficacy, safety, or tolerability, as well as through competitive pricing and reimbursement strategies. Meanwhile, national healthcare cost-control measures and volume-based procurement policies exert pricing pressure, but also help improve patient accessibility and drive market uptake. Overall, its market prospects will depend on clinical data performance, long-term safety in chronic use, and its positioning in first-line or alternative therapy, as well as its comprehensive competitiveness in pricing, distribution channels, and academic promotion.
    This report is a detailed and comprehensive analysis for global Flumatinib Mesylate market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Flumatinib Mesylate market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Flumatinib Mesylate market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Flumatinib Mesylate market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Flumatinib Mesylate market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Flumatinib Mesylate
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Flumatinib Mesylate market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Jiangsu Hansoh Pharmaceutical Group, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Flumatinib Mesylate market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    200 mg/Tablet
    400 mg/Tablet
    Market segment by Sales Channels
    Hospital
    Retail pharmacy
    Online
    Market segment by Pharmaceutical Technology
    Innovative drug
    Generic drug
    Market segment by Application
    Chronic Myeloid Leukemia (CML)
    Tyrosine Kinase Inhibitor (TKI)
    Others
    Major players covered
    Jiangsu Hansoh Pharmaceutical Group
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Flumatinib Mesylate product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Flumatinib Mesylate, with price, sales quantity, revenue, and global market share of Flumatinib Mesylate from 2021 to 2026.
    Chapter 3, the Flumatinib Mesylate competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Flumatinib Mesylate breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Flumatinib Mesylate market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Flumatinib Mesylate.
    Chapter 14 and 15, to describe Flumatinib Mesylate sales channel, distributors, customers, research findings and conclusion.

    Buy now